Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

281 trials

NCT07611214
Recruiting
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Phase 4 · United States · 27 sites
Registry update: 3 Aug 2026
NCT07260942
Recruiting
Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
Not applicable · France · 1 site
Registry update: 18 May 2026
NCT07409181
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Phase 2 · Argentina, Australia, Bulgaria, Brazil, China, Colombia, Germany, Spain, United Kingdom, Croatia, Hungary, India, Japan, Mexico, Netherlands, Poland, Romania, Serbia, Taiwan, United States, South Africa · 140 sites
Registry update: 28 Oct 2026
NCT07430306
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Phase 3 · Canada, Germany, Spain, France, Italy, Mexico, Poland, Taiwan, United States · 88 sites
Registry update: 25 Sept 2026
NCT07405970
Recruiting
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Phase 3 · China · 1 site
Registry update: 5 May 2026
NCT07629596
Recruiting
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
Early phase 1 · China · 1 site
Registry update: 5 Jun 2026
NCT07299422
Recruiting
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
Phase 2 · China · 2 sites
Registry update: 29 Sept 2026
NCT07355218
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Phase 3 · Australia, Belgium, Bulgaria, Brazil, Canada, Switzerland, China, Czechia, Germany, Spain, France, United Kingdom, Greece, Israel, Italy, South Korea, Poland, Romania, Thailand, Taiwan, United States, South Africa · 89 sites
Registry update: 4 Nov 2026
NCT07515014
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
Phase 2 · China, Japan, South Korea, Taiwan · 54 sites
Registry update: 21 Aug 2026
NCT07447986
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
Phase 2 · China · 40 sites
Registry update: 17 Sept 2026
NCT07526350
Recruiting
MTS109 in Patients With Refractory Autoimmune Diseases
Early phase 1 · China · 1 site
Registry update: 30 Jun 2026
NCT07491900
Recruiting
A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
Phase 1 · Australia · 1 site
Registry update: 25 Mar 2026
NCT07490041
Recruiting
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
Early phase 1 · China · 1 site
Registry update: 24 Mar 2026
NCT06947473
Recruiting
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/2 · China · 1 site
Registry update: 3 Mar 2026
NCT07219563
Recruiting
Alnuctamab for Refractory SLE (LATTE Study)
Phase 1 · United States · 1 site
Registry update: 21 Apr 2026
NCT07087912
Recruiting
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Phase 4 · Brazil · 2 sites
Registry update: 20 Jul 2026
NCT07470151
Recruiting
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Not applicable · China · 1 site
Registry update: 13 Mar 2026
NCT07332481
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Phase 3 · Australia, Belgium, Bulgaria, Brazil, Switzerland, China, Germany, Spain, France, United Kingdom, Greece, Israel, Italy, Japan, South Korea, Poland, Romania, Slovakia, Thailand, Taiwan, United States · 92 sites
Registry update: 4 Nov 2026
NCT07438496
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Phase 3 · Argentina, Australia, Bulgaria, Brazil, Switzerland, China, Czechia, Germany, Denmark, Spain, Finland, France, United Kingdom, Georgia, Greece, Hungary, Israel, Italy, Japan, South Korea, Mexico, Malaysia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Thailand, Taiwan, United States, South Africa · 273 sites
Registry update: 3 Nov 2026
NCT07523542
Recruiting
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Phase 1/2 · China · 1 site
Registry update: 13 Apr 2026

Ordered by registry start date. Freshness and sponsorship never change the order.